US EditionPublished • loading... • Updated
Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Palleon Pharmaceuticals Presents First-in-Class B7-H3 Targeted Sialidase at the 2026 AACR Annual Meeting
E-688/HLX316 activates both innate and adaptive anti-tumor immunity through tumor-targeted enzymatic desialylation Initiation of a first-in-human clinical trial of E-688/HLX316 is underway in China, following IND approval granted to strategic collaborator Henlius by the National Medical Products Administration (NMPA)WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals today presented preclinical data and announced the initiation of a human c…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
